寵物抗癌藥物市場規模、佔有率、成長分析（按生物體、治療方法、給藥途徑、癌症類型和地區）- 產業預測，2025-2032 年

寵物抗癌藥物市場規模預計將在 2023 年達到 4.02 億美元，從 2024 年的 4.414 億美元成長到 2032 年的 9.325 億美元，在預測期內（2025-2032 年）的複合年成長率為 9.8%。

隨著寵物飼主對寵物健康的認知不斷提高，全球寵物抗癌藥物市場正經歷顯著成長。這種有利於動物福利的轉變正在推動對有效癌症治療方案的需求增加。對此，業內公司正在開發專門針對寵物的新型治療藥物，旨在改善寵物罹患癌症的治療效果和整體生活品質。此外，獸醫腫瘤學的進步提高了我們對寵物癌症的認知，並導致了標靶治療的產生。這種不斷發展的市場環境反映了對動物的關懷與尖端科學進步之間的良好交匯，最終解決了對抗癌症的寵物的特殊醫療需求。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 監管分析

寵物癌症治療藥物市場規模（按類型）

• 市場概況
• 狗
• 貓
• 其他類型

寵物癌症治療市場規模

• 市場概況
• 化療
• 免疫療法
• 標靶治療
• 聯合治療

寵物癌症治療藥物市場規模（依給藥途徑）

• 市場概況
• 口服
• 注射

寵物癌症治療藥物市場規模（依癌症類型）

• 市場概況
• 淋巴瘤
• 肥大細胞癌
• 惡性黑色素瘤
• 乳腺腺癌和鱗狀細胞癌
• 其他癌症

寵物癌症治療藥物市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司詳細資訊
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Elanco Animal Health（US）
• Anivive Lifesciences（US）
• Regeneus（Australia）
• Qbiotics（Australia）
• Zoetis（US）
• VetDC（US）
• AB Science（France）
• Vet Cancer Group（US）
• VetriScience（US）
• Vetnostics（Australia）
• Veterinary Cancer Society（US）
• PetCure Oncology（US）
• Oasmia Pharmaceutical（Sweden）

結論和建議

Pet Cancer Therapeutics Market size was valued at USD 402.0 million in 2023 and is poised to grow from USD 441.4 million in 2024 to USD 932.5 million by 2032, growing at a CAGR of 9.8% during the forecast period (2025-2032).

The global pet cancer therapeutics market is experiencing significant growth due to heightened awareness among pet owners regarding their furry companions' health. This shift towards prioritizing animal welfare has catalyzed an increased demand for effective cancer treatment options. In response, industry players are innovating new therapeutics specifically designed for pets, aiming to enhance treatment outcomes and overall quality of life for those facing cancer diagnoses. Furthermore, advancements in veterinary oncology are deepening the understanding of pet cancer, leading to the creation of targeted therapies. This evolving market landscape reflects a promising intersection of compassion for animals and cutting-edge scientific progress, ultimately addressing the specialized healthcare needs of pets battling cancer.

Top-down and bottom-up approaches were used to estimate and validate the size of the Pet Cancer Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Pet Cancer Therapeutics Market Segments Analysis

Global Pet Cancer Therapeutics Market is segmented by Species, Therapy, Route of Administration, Cancer Type and region. Based on Species, the market is segmented into Dogs, Cats and Other species. Based on Therapy, the market is segmented into Chemotherapy, Immunotherapy, Targeted therapy and Combination therapy. Based on Route of Administration, the market is segmented into Oral and Injection. Based on Cancer Type, the market is segmented into Lymphoma, Mast cell cancer, Melanoma, Mammary and squamous cell cancer and Other cancer types. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Pet Cancer Therapeutics Market

One of the primary drivers propelling the global pet cancer therapeutics market is the growing trend of pet humanization. As pet owners increasingly perceive their pets as cherished family members, there is a heightened readiness to invest in sophisticated healthcare solutions, particularly for cancer treatments. This shift in perspective enhances the demand for effective and compassionate cancer therapies specifically designed for pets, fostering both innovation and expansion within the market. The commitment to providing superior care for beloved animals is fundamentally transforming the landscape of veterinary oncology, leading to advancements and a wider array of therapeutic options.

Restraints in the Pet Cancer Therapeutics Market

A major challenge facing the global pet cancer therapeutics market is the significant financial burden that cancer treatments impose on pet owners. The costs associated with various procedures and medications, including diagnostics, surgeries, radiation therapy, and pharmaceuticals, can be quite high. This economic strain may restrict many pet owners from accessing advanced cancer care options, ultimately forcing them to make tough choices regarding the level of treatment they can provide for their companions. Consequently, despite the growing awareness and demand for effective pet cancer therapeutics, the issue of affordability persists as a vital concern, affecting market dynamics and limiting the availability of these essential treatments.

Market Trends of the Pet Cancer Therapeutics Market

The global pet cancer therapeutics market is witnessing a notable trend centered around personalized treatment strategies. As pet owners and veterinarians increasingly acknowledge the distinct nature of each pet's cancer, there is a growing demand for customized therapeutic solutions, including precision medicine and targeted therapies. Innovations in diagnostics, such as genetic profiling and molecular testing, facilitate more accurate cancer diagnoses, enabling tailored treatment plans that align with the specific tumor characteristics of each pet. This focus on individualized care not only enhances treatment efficacy but also minimizes adverse side effects, reflecting a broader commitment to improving the quality of care and outcomes for pets battling cancer.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Analysis

Global Pet Cancer Therapeutics Market Size by Species & CAGR (2025-2032)

• Market Overview
• Dogs
• Cats
• Other species

Global Pet Cancer Therapeutics Market Size by Therapy & CAGR (2025-2032)

• Market Overview
• Chemotherapy
• Immunotherapy
• Targeted therapy
• Combination therapy

Global Pet Cancer Therapeutics Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Injection

Global Pet Cancer Therapeutics Market Size by Cancer Type & CAGR (2025-2032)

• Market Overview
• Lymphoma
• Mast cell cancer
• Melanoma
• Mammary and squamous cell cancer
• Other cancer types

Global Pet Cancer Therapeutics Market Size & CAGR (2025-2032)

• North America (Species, Therapy, Route of Administration, Cancer Type)
  • US
  • Canada
• Europe (Species, Therapy, Route of Administration, Cancer Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Species, Therapy, Route of Administration, Cancer Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Species, Therapy, Route of Administration, Cancer Type)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Species, Therapy, Route of Administration, Cancer Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Elanco Animal Health (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anivive Lifesciences (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneus (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qbiotics (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zoetis (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• VetDC (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AB Science (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vet Cancer Group (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• VetriScience (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetnostics (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Veterinary Cancer Society (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PetCure Oncology (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oasmia Pharmaceutical (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations